HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental Data All Versions of this Article: jnumed.108.056929v1 50/5/781    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ahlgren, S. Articles by Tolmachev, V. Search for Related Content PubMed PubMed Citation Articles by Ahlgren, S. Articles by Tolmachev, V.

Targeting of HER2-Expressing Tumors with a Site-Specifically ^99mTc-Labeled Recombinant Affibody Molecule, Z_HER2:2395, with C-Terminally Engineered Cysteine

¹ Division of Nuclear Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ² Affibody AB, Bromma, Sweden; ³ Rudbeck Laboratory, Division of Biomedical Radiation Sciences, Department of Radiology, Oncology, and Clinical Immunology, Uppsala University, Uppsala, Sweden; ⁴ Hospital Physics, Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; and ⁵ Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany

Correspondence: For correspondence or reprints contact: Vladimir Tolmachev, Rudbeck Laboratory, Division of Biomedical Radiation Sciences, Uppsala University, SE-751 85 Uppsala, Sweden. E-mail: Vladimir.Tolmachev{at}bms.uu.se

The detection of human epidermal growth factor receptor type 2 (HER2) expression in malignant tumors provides important information influencing patient management. Radionuclide in vivo imaging of HER2 may permit the detection of HER2 in both primary tumors and metastases by a single noninvasive procedure. Small (7 kDa) high-affinity anti-HER2 Affibody molecules may be suitable tracers for SPECT visualization of HER2-expressing tumors. The use of generator-produced ^99mTc as a label would facilitate the prompt translation of anti-HER2 Affibody molecules into use in clinics. Methods: A C-terminal cysteine was introduced into the Affibody molecule Z_HER2:342 to enable site-specific labeling with ^99mTc. Two recombinant variants, His₆-Z_HER2:342-Cys (dissociation constant [K_D], 29 pM) and Z_HER2:2395-Cys, lacking a His tag (K_D, 27 pM), were labeled with ^99mTc in yields exceeding 90%. The binding specificity and the cellular processing of Affibody molecules were studied in vitro. Biodistribution and -camera imaging studies were performed in mice bearing HER2-expressing xenografts. Results: ^99mTc-His₆-Z_HER2:342-Cys was capable of targeting HER2-expressing SKOV-3 xenografts in SCID mice, but the liver radioactivity uptake was high. A series of comparative biodistribution experiments indicated that the presence of the His tag caused elevated accumulation in the liver. ^99mTc-Z_HER2:2395-Cys, not containing a His tag, showed low uptake in the liver and high and specific uptake in HER2-expressing xenografts. Four hours after injection, the radioactivity uptake values (percentage of injected activity per gram of tissue [%IA/g]) were 6.9 ± 2.5 (mean ± SD) %IA/g in LS174T xenografts (moderate level of HER2 expression) and 15 ± 3 %IA/g in SKOV-3 xenografts (high level of HER2 expression). The corresponding tumor-to-blood ratios were 88 ± 24 and 121 ± 24, respectively. Both LS174T and SKOV-3 xenografts were clearly visualized with a clinical -camera 1 h after injection of ^99mTc-Z_HER2:2395-Cys. Conclusion: The Affibody molecule ^99mTc-Z_HER2:2395-Cys is a promising tracer for SPECT visualization of HER2-expressing tumors.

Key Words: Affibody molecule • technetium • imaging • HER2 • C-terminal cysteine

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]